Dear Diana,
Thank you for this wonderful information. I have been told by many women
with Ovarian cancer that they are platinum resistant and not been able
to either tolerate the platinum chemo family or be administered with
this chemo. This news comes at a time as many other new treatments do
that provides that much more hope for all. Thank you
God Bless
marty auslander
LINHILLIS wrote:
>
> Dear All
>
> Thought some of you might be interested in this information.
> God Bless
> Diana
>
> ---------------------------------------------------------------
>
> Subject: Zeneca Agreement with AnorMED on Anti-Cancer Agent...
> Date: Tue, 14 Apr 1998 11:07:43 EDT
> From: AOL News <AOLNews@aol.com>
> Organization: AOL (http://www.aol.com)
>
> Zeneca Agreement with AnorMED on Anti-Cancer Agent Strengthens Oncology
> Development Portfolio
>
> WILMINGTON, Del., April 14 /PRNewswire/ -- Zeneca Limited and AnorMED Inc.
> have reached an agreement whereby AnorMED will exclusively license to Zeneca
> their anti-cancer agent AMD473 for further development and commercialization
> by Zeneca.
>
> AMD473 is a third generation platinum compound which has shown activity
> against cisplatin- and carboplatin-resistant tumors in animal studies. It has
> potential to treat tumors in humans which have proved resistant to existing
> treatments. Possible targets include non-small-cell lung carcinoma, and
> ovarian, lung, colorectal, and bladder cancers. Phase I clinical trials
> commenced in late 1997.
>
> Under the terms of the agreement, there has been an initial payment by Zeneca
> in consideration for patent rights, recognizing AnorMED's research and early
> development efforts to date on AMD473. In addition, there will be further
> milestone payments linked to the achievement of development and
> commercialization targets. The agreement also includes provision for the
> payment of royalties, which will vary according to the level of product sales
> achieved. Zeneca will assume responsibility for the worldwide development and
> commercialization of this promising anti-cancer agent.
>
> Dr. Richard Auty, Research and Development Director for Zeneca Pharmaceuticals
> said, "I am delighted that we have been able to enter into this agreement with
> AnorMED. AMD473 provides a significant opportunity to add another novel
> cytotoxic agent to Zeneca's broadening development portfolio in the oncology
> area. Our continuing success in identifying worthwhile licensing
> opportunities is now firmly established as an important aspect of our progress
> to becoming the world's leading oncology company."
>
> Dr. Michael J. Abrams, Chief Executive Officer of AnorMED said, "We believe
> that AMD473 has exciting potential for the treatment of a range of tumors and,
> to realize that potential, it was important that this compound be licensed for
> clinical development and commercialization to an appropriate major
> pharmaceutical company. Zeneca provides that opportunity with its proven
> track record of successful developments in the oncology area and AnorMED looks
> forward to collaborating with Zeneca to ensure a successful outcome."
>
> Over the last three years, Zeneca has launched three new anti-cancer drugs -
> ARIMIDEX(R) (anastrozole), for treating advanced breast cancer in post
> menopausal women; CASODEX(R) (bicalutamide), an oral anti-androgen for the
> treatment of advanced prostate cancer; and TOMUDEX(R) (raltitrexed), a
> thymidylate synthase inhibitor for the palliative treatment of advanced
> colorectal cancer. NOLVADEX(R) (tamoxifen citrate), first launched in 1973,
> was the original hormonal anti-cancer drug discovered, developed, manufactured
> and marketed by Zeneca Pharmaceuticals. It is now the world's leading
> hormonal breast cancer medicine and has recently been shown, in a U.S. breast
> cancer prevention study carried out by the National Cancer Institute and
> National Surgical Adjuvant Bowel and Breast Project, that women at increased
> risk of developing breast cancer who took it were 45 percent less likely to
> develop breast cancer than women who received placebo.
>
> In 1997, Zeneca Pharmaceuticals spent 33 percent of its $729 million R&D
> expenditure in the cancer area and there are already seven anti-cancer
> compounds in development. This development portfolio includes potential new
> treatments for breast, colorectal and non-small-cell lung cancer. Of these,
> closest to commercialization is FASLODEX(R) (ZD 9238), a pure anti-estrogen
> which is currently in Phase III clinical development for patients with
> advanced breast cancer.
>
> AnorMED is a pharmaceutical company based in Langley, British Columbia,
> Canada, specializing in the pharmaceutical applications of metal and metal
> binding compounds for the treatment of a variety of diseases including cancer
> and AIDS. The Company's business strategy includes product development,
> manufacturing, and marketing through corporate partnerships. AnorMED has
> extensive experience in the development of novel platinum-based oncology drugs
> such as AMD473. The development of AMD473 has arisen from a long-standing
> collaboration with the UK Cancer Research Campaign (CRC) and the CRC Centre
> for Cancer Therapeutics at the Institute of Cancer Research.
>
> Zeneca is a $3.6 billion bioscience business with approximately 7,800
> employees in the United States and Canada. Zeneca Inc. (in the US) and Zeneca
> Corp. (in Canada) are both wholly owned subsidiaries of the UK-based Zeneca
> Group PLC (NYSE: ZEN), a major $8.6 billion international bioscience business
> engaged in the research, development, manufacture and marketing of ethical
> (prescription) pharmaceuticals, agricultural and specialty chemical products,
> and the supply of healthcare services.
>
> SOURCE Zeneca Pharmaceuticals
>
> CO: Zeneca Group PLC; Zeneca Pharmaceuticals; Zeneca Limited; AnorMED Inc.
>
> ST: Delaware, British Columbia
>
> IN: MTC
>
> SU: LIC
>
> 04/14/98 11:02 EDT http://www.prnewswire.com
>
> To edit your profile, go to keyword <A HREF="aol://1722:NewsProfiles">
> NewsProfiles</A>.
> For all of today's news, go to keyword <A HREF="aol://1722:News">News</A>.
------------------------------------------------------------------------
This is an automatically-generated notice. If you'd like to be removed
from the mailing list, please visit the Medicine-On-Line Discussion Forum
at <http://www.meds.com/con_faq.html>, or send an email message to:
majordomo@lists.meds.com
with the subject line blank and the body of the message containing the line:
unsubscribe mol-cancer your-email-address
where the phrase your-email-address is replaced with your actual email
address.
------------------------------------------------------------------------
